Rona Therapeutics

Rona Therapeutics was founded in 2021 with the aim of establishing its own platform to develop innovative and disruptive nucleic acid drugs, providing high specificity, stability, and long-acting properties to therapeutics. Leveraging its proprietary delivery platform, Rona Therapeutics’ nucleic acid drugs are developed through a modular and programmable approach, primarily targeting disease areas such as metabolism, central nervous system, ophthalmology, and oncology. The company is building a state-of-the-art R&D facility system equipped with cutting-edge technology to expand capabilities in nucleic acid synthesis, delivery platforms, oligonucleotide chemical modifications, nucleic acid biology, bioinformatics, and technology-driven nucleic acid manufacturing, ultimately realizing the exceptional potential of nucleic acid therapeutics.